165 related articles for article (PubMed ID: 33896649)
21. High efficacy of PD-1 inhibitor after initial failure of PD-L1 inhibitor in Relapsed/Refractory classical Hodgkin Lymphoma.
Chen X; Kong H; Luo L; Han S; Lei T; Yu H; Guo N; Li C; Peng S; Dong X; Yang H; Wu M
BMC Cancer; 2022 Jan; 22(1):9. PubMed ID: 34980000
[TBL] [Abstract][Full Text] [Related]
22. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
[TBL] [Abstract][Full Text] [Related]
23. Expression of Grb2 distinguishes classical Hodgkin lymphomas from primary mediastinal B-cell lymphomas and other diffuse large B-cell lymphomas.
Miles RR; Mankey CC; Seiler CE; Smith LB; Teruya-Feldstein J; Hsi ED; Elenitoba-Johnson KS; Lim MS
Hum Pathol; 2009 Dec; 40(12):1731-7. PubMed ID: 19716163
[TBL] [Abstract][Full Text] [Related]
24. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
25. Comparative pathologic analysis of mediastinal B-cell lymphomas: selective expression of p63 but no GATA3 optimally differentiates primary mediastinal large B-cell lymphoma from classic Hodgkin lymphoma.
Kim HJ; Kim HK; Park G; Min SK; Cha HJ; Lee H; Choi SJ; Na HY; Choe JY; Kim JE
Diagn Pathol; 2019 Dec; 14(1):133. PubMed ID: 31831043
[TBL] [Abstract][Full Text] [Related]
26. Clinical PD-1/PD-L1 Blockades in Combination Therapies for Lymphomas.
Katsuya H; Suzumiya J; Kimura S
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001659
[TBL] [Abstract][Full Text] [Related]
27. Gene Expression Profiling of Mediastinal Gray Zone Lymphoma and Its Relationship to Primary Mediastinal B-cell Lymphoma and Classical Hodgkin Lymphoma.
Pittaluga S; Nicolae A; Wright GW; Melani C; Roschewski M; Steinberg S; Huang D; Staudt LM; Jaffe ES; Wilson WH
Blood Cancer Discov; 2020 Sep; 1(2):155-161. PubMed ID: 32914098
[TBL] [Abstract][Full Text] [Related]
28. Immune checkpoint inhibitors in malignant lymphoma: Advances and perspectives.
Lin N; Song Y; Zhu J
Chin J Cancer Res; 2020 Jun; 32(3):303-318. PubMed ID: 32694896
[TBL] [Abstract][Full Text] [Related]
29. Soluble programmed cell death protein 1 (sPD-1) and the soluble programmed cell death ligands 1 and 2 (sPD-L1 and sPD-L2) in lymphoid malignancies.
Mortensen JB; Monrad I; Enemark MB; Ludvigsen M; Kamper P; Bjerre M; d'Amore F
Eur J Haematol; 2021 Jul; 107(1):81-91. PubMed ID: 33721375
[TBL] [Abstract][Full Text] [Related]
30. Primary mediastinal B-cell lymphoma and mediastinal gray zone lymphoma: do they require a unique therapeutic approach?
Dunleavy K; Wilson WH
Blood; 2015 Jan; 125(1):33-9. PubMed ID: 25499450
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of PD-1/PD-L1 expression and prognostic relevance in non-Hodgkin lymphoma: a summary of immunohistochemical studies.
Gravelle P; Burroni B; PƩricart S; Rossi C; Bezombes C; Tosolini M; Damotte D; Brousset P; FourniƩ JJ; Laurent C
Oncotarget; 2017 Jul; 8(27):44960-44975. PubMed ID: 28402953
[TBL] [Abstract][Full Text] [Related]
32. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy.
Camus V; Bigenwald C; Ribrag V; Lazarovici J; Jardin F; Sarkozy C
Expert Rev Anticancer Ther; 2021 Sep; 21(9):941-956. PubMed ID: 34233557
[No Abstract] [Full Text] [Related]
33. Immunophenotyping of the PD-L1-positive cells in angioimmunoblastic T cell lymphoma and Hodgkin disease.
Tiemann M; Samoilova V; Atiakshin D; Buchwalow I
BMC Res Notes; 2020 Mar; 13(1):139. PubMed ID: 32143684
[TBL] [Abstract][Full Text] [Related]
34. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma.
Traverse-Glehen A; Pittaluga S; Gaulard P; Sorbara L; Alonso MA; Raffeld M; Jaffe ES
Am J Surg Pathol; 2005 Nov; 29(11):1411-21. PubMed ID: 16224207
[TBL] [Abstract][Full Text] [Related]
35. GATA3 Immunohistochemical Staining in Hodgkin Lymphoma: Diagnostic Utility in Differentiating Classic Hodgkin Lymphoma From Nodular Lymphocyte Predominant Hodgkin Lymphoma and Other Mimicking Entities.
Kezlarian B; Alhyari M; Venkataraman G; Karner K; Inamdar KV; Menon MP
Appl Immunohistochem Mol Morphol; 2019 Mar; 27(3):180-184. PubMed ID: 28877074
[TBL] [Abstract][Full Text] [Related]
36. Molecular profiling provides evidence of primary mediastinal large B-cell lymphoma as a distinct entity related to classic Hodgkin lymphoma: implications for mediastinal gray zone lymphomas as an intermediate form of B-cell lymphoma.
Calvo KR; Traverse-Glehen A; Pittaluga S; Jaffe ES
Adv Anat Pathol; 2004 Sep; 11(5):227-38. PubMed ID: 15322489
[TBL] [Abstract][Full Text] [Related]
37. Primary mediastinal B-cell lymphoma: hypermutation of the BCL6 gene targets motifs different from those in diffuse large B-cell and follicular lymphomas.
Malpeli G; Barbi S; Moore PS; Scardoni M; Chilosi M; Scarpa A; Menestrina F
Haematologica; 2004 Sep; 89(9):1091-9. PubMed ID: 15377470
[TBL] [Abstract][Full Text] [Related]
38. Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma.
Guiter C; Dusanter-Fourt I; Copie-Bergman C; Boulland ML; Le Gouvello S; Gaulard P; Leroy K; Castellano F
Blood; 2004 Jul; 104(2):543-9. PubMed ID: 15044251
[TBL] [Abstract][Full Text] [Related]
39. Primary mediastinal large B-cell lymphoma: transcriptional regulation by miR-92a through FOXP1 targeting.
Romero M; Gapihan G; Castro-Vega LJ; Acevedo A; Wang L; Li ZW; El Bouchtaoui M; Di Benedetto M; Ratajczak P; Feugeas JP; Thieblemont C; Saavedra C; Janin A
Oncotarget; 2017 Mar; 8(10):16243-16258. PubMed ID: 27806315
[TBL] [Abstract][Full Text] [Related]
40. Pembrolizumab for the treatment of diffuse large B-cell lymphoma.
Sheikh S; Kuruvilla J
Expert Opin Biol Ther; 2019 Nov; 19(11):1119-1126. PubMed ID: 31456438
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]